Iran manufactures the large majority of the medicines it consumes by volume and has built biotech capability in biosimilars and vaccines that is unusual for the region.
The import gap is in high-value therapeutics, advanced medical devices and diagnostics — precisely where a foreign technology partner adds capability rather than competing with domestic producers.
Regulatory pathway
The Iran FDA controls registration, pricing and import licensing for medicines and devices. Registration timelines depend heavily on whether an equivalent domestic product exists — protection of local manufacture is an explicit policy objective.
Local manufacturing or fill-finish partnerships shorten market access considerably compared with a pure import registration.
Devices and diagnostics
Imaging, laboratory automation, interventional cardiology and oncology equipment are consistently import-dependent, with service and consumables representing the durable revenue rather than the capital sale.
Distributor selection is the main commercial risk: after-sales service capability, not price, determines whether an installed base grows.
Medical tourism
Iran receives significant inbound medical travel from neighbouring countries for surgery, fertility treatment and ophthalmology, driven by cost and clinical reputation.
Investment opportunities lie in hospital capacity, accredited private clinics and the hospitality and coordination layer around them.